WO2016207782A1 - Oligopeptides synthétiques immunogènes pour un vaccin contre le vih - Google Patents

Oligopeptides synthétiques immunogènes pour un vaccin contre le vih Download PDF

Info

Publication number
WO2016207782A1
WO2016207782A1 PCT/IB2016/053669 IB2016053669W WO2016207782A1 WO 2016207782 A1 WO2016207782 A1 WO 2016207782A1 IB 2016053669 W IB2016053669 W IB 2016053669W WO 2016207782 A1 WO2016207782 A1 WO 2016207782A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
olpen
pentapeptides
antigen
amino acid
Prior art date
Application number
PCT/IB2016/053669
Other languages
English (en)
Inventor
Jean-Pierre Spinosa
Original Assignee
STRELNIKOV, Evgeny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STRELNIKOV, Evgeny filed Critical STRELNIKOV, Evgeny
Publication of WO2016207782A1 publication Critical patent/WO2016207782A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne un procédé de production d'oligopeptides synthétiques immunogènes pour un vaccin contre le VIH. Les oligopeptides sont formés par des déterminants d'immunité minimaux exclusivement présents dans des antigènes d'intérêt et qui sont utiles pour susciter des réponses immunitaires spécifiques, efficaces et ne provoquant pas de réaction croisée dans des immunothérapies et des immunodiagnostics. Les déterminants sont connectés les uns aux autres par des lieurs, chaque lieur contenant au moins un élément qui n'est pas un acide aminé humain. L'invention concerne également une préparation pharmaceutique, telle qu'un vaccin, qui comprend lesdits oligopeptides synthétiques immunogènes.
PCT/IB2016/053669 2015-06-22 2016-06-21 Oligopeptides synthétiques immunogènes pour un vaccin contre le vih WO2016207782A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2015054664 2015-06-22
IBPCT/IB2015/054664 2015-06-22

Publications (1)

Publication Number Publication Date
WO2016207782A1 true WO2016207782A1 (fr) 2016-12-29

Family

ID=56740265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/053669 WO2016207782A1 (fr) 2015-06-22 2016-06-21 Oligopeptides synthétiques immunogènes pour un vaccin contre le vih

Country Status (1)

Country Link
WO (1) WO2016207782A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036087A1 (fr) * 1997-02-13 1998-08-20 American National Red Cross Tolerance immunologique aux epitopes du hiv
US20070111261A1 (en) * 2001-11-23 2007-05-17 Applied Immune Technologies, Inc. Antigens
WO2009109428A2 (fr) * 2008-02-01 2009-09-11 Alpha-O Peptides Ag Nanoparticules peptidiques à auto-assemblage utiles comme vaccins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036087A1 (fr) * 1997-02-13 1998-08-20 American National Red Cross Tolerance immunologique aux epitopes du hiv
US20070111261A1 (en) * 2001-11-23 2007-05-17 Applied Immune Technologies, Inc. Antigens
WO2009109428A2 (fr) * 2008-02-01 2009-09-11 Alpha-O Peptides Ag Nanoparticules peptidiques à auto-assemblage utiles comme vaccins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUGLIELMO LUCCHESE ET AL: "Searching for an effective, safe and universal anti-HIV vaccine: Finding the answer in just one short peptide", SELF NONSELF - IMMUNE RECOGNITION AND SIGNALING, vol. 2, no. 1, 1 January 2011 (2011-01-01), US, pages 49 - 54, XP055308478, ISSN: 1938-2030, DOI: 10.4161/self.2.1.14762 *
KANDUC D: "'Self-nonself' peptides in the design of vaccines", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 15, no. 28, 1 January 2009 (2009-01-01), pages 3283 - 3289, XP009183183, ISSN: 1381-6128 *

Similar Documents

Publication Publication Date Title
DK2023952T3 (en) Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
Layton et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3: Ty-virus-like particles.
ES2336393T3 (es) Complejo antigenico que comprende un inmoestimulador, cd4, y un dominio receptor de quimioquina para tratamiento de vih y desordenes inmunes.
Deliyannis et al. Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus
Arnon Chemically defined antiviral vaccines
US20100121029A1 (en) Anti-hiv immunogenic formulation and process for preparation thereof
Karpenko et al. Novel approaches in polyepitope T-cell vaccine development against HIV-1
JP2016501850A (ja) 口蹄疫（ｆｍｄ）に対する合成ペプチドベースの緊急ワクチン
MacRaild et al. Disordered epitopes as peptide vaccines
Apellániz et al. The use of liposomes to shape epitope structure and modulate immunogenic responses of peptide vaccines against HIV MPER
CA2500401A1 (fr) Peptides antigeniques
US20210052720A1 (en) Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositions
Karch et al. Self-assembling protein nanoparticles: implications for HIV-1 vaccine development
WO2016207782A1 (fr) Oligopeptides synthétiques immunogènes pour un vaccin contre le vih
EP3007090A1 (fr) Oligopeptides synthétiques immunogènes
WO2016207781A1 (fr) Oligopeptides synthétiques immunogènes pour vaccin dirigé contre le bacille de koch
WO2016207779A1 (fr) Oligopeptides synthétiques immunogènes
WO2016055963A1 (fr) Construction d'oligopeptides synthétiques immunogènes
Gao et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies
Gravel et al. Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages
Kanduc Peptides for anti-Ebolavirus vaccines
Peet et al. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV‐1 gp120
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
AU2002231510B2 (en) Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
US20060204514A1 (en) Expression of hydrophobic proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16753967

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16753967

Country of ref document: EP

Kind code of ref document: A1